Topoisomerase inhibitors modulate expression of melanocytic antigens and enhance T cell recognition of tumor cellsHAGGERTY, Timothy J; DUNN, Ian S; ROSE, Lenora B et al.Cancer immunology and immunotherapy. 2011, Vol 60, Num 1, pp 133-144, issn 0340-7004, 12 p.Article

Melan-A/MART1 Analog Peptide Triggers Anti-myeloma T-cells Through Crossreactivity With HM1.24CHRISTENSEN, Olaf; LUPU, Alaviana; TERNESS, Peter et al.Journal of immunotherapy (1997). 2009, Vol 32, Num 6, pp 613-621, issn 1524-9557, 9 p.Article

Generation of a prophylactic melanoma vaccine using whole recombinant yeast expressing MART-1RIEMANN, Helge; TAKAO, Joe; SHELLMAN, Yiqun G et al.Experimental dermatology. 2007, Vol 16, Num 10, pp 814-822, issn 0906-6705, 9 p.Article

Immunocytochemical detection of MART-1 in fresh and paraffin-embedded malignant melanomasFETSCH, P. A; CORMIER, J; HIJAZI, Y. M et al.Journal of immunotherapy with emphasis on tumor immunology. 1997, Vol 20, Num 1, pp 60-64, issn 1067-5582Article

Stealth Melanoma Cells in Histology-negative Sentinel Lymph NodesITAKURA, Eijun; HUANG, Rong-Rong; WEN, Duan-Ren et al.The American journal of surgical pathology. 2011, Vol 35, Num 11, pp 1657-1665, issn 0147-5185, 9 p.Article

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumorKAWAKAMI, Y; ELIYAHU, S; DELGADO, C. H et al.Proceedings of the National Academy of Sciences of the United States of America. 1994, Vol 91, Num 9, pp 3515-3519, issn 0027-8424Article

Establishment of gp100 and MART-1/Melan-A-specific cytotoxic T lymphocyte clones using in vitro immunization against preselected highly immunogenic melanoma cell clonesKIRKIN, A. F; STRATEN, P. T; HANSEN, M. R et al.Cancer immunology and immunotherapy. 1999, Vol 48, Num 5, pp 239-246, issn 0340-7004Article

Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanomaWANG, F; BADE, E; KUNIYOSHI, C et al.Clinical cancer research. 1999, Vol 5, Num 10, pp 2756-2765, issn 1078-0432Article

Improved detection of melanoma antigen-specific T cells expressing low or high levels of CD8 by HLA-A2 tetramers presenting a melan-A/mart-1 peptide analogueMAEURER, Markus J; NECKER, Antje; SALTER, Russell D et al.International journal of cancer. 2002, Vol 97, Num 1, pp 64-71, issn 0020-7136Article

Detection of microscopic melanoma metastases in sentinel lymph nodesYU, L. L; FLOTTE, T. J; TANABE, K. K et al.Cancer. 1999, Vol 86, Num 4, pp 617-627, issn 0008-543XArticle

MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastasesCURRY, B. J; MYERS, K; HERSEY, P et al.Journal of clinical oncology. 1999, Vol 17, Num 8, pp 2562-2571, issn 0732-183XArticle

Monophosphoryl lipid A plus IFNγ maturation of dendritic cells induces antigen-specific CD8⁺ cytotoxic T cells with high cytolytic potentialTEN BRINKE, Anja; VAN SCHIJNDEL, Gijs; VISSER, Remco et al.Cancer immunology and immunotherapy. 2010, Vol 59, Num 8, pp 1185-1195, issn 0340-7004, 11 p.Article

Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic MelanomaCHODON, Thinle; COMIN-ANDUIX, Begoña; MCCANNEL, Tara A et al.Clinical cancer research (Print). 2014, Vol 20, Num 9, pp 2457-2465, issn 1078-0432, 9 p.Article

Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cellsBAUMGAERTNER, Petra; JANDUS, Camilla; RUFER, Nathalie et al.International journal of cancer (Print). 2012, Vol 130, Num 11, pp 2607-2617, issn 0020-7136, 11 p.Article

Identification of an HLA-DPB1*0501 Restricted Melan-A/MART-1 Epitope Recognized by CD4⁺ T Lymphocytes: Prevalence for Immunotherapy in Asian PopulationsZHAOTING MENG; YADONG WANG; SHUNCHANG JIAO et al.Journal of immunotherapy (1997). 2011, Vol 34, Num 7, pp 525-534, issn 1524-9557, 10 p.Article

Memory and Effector CD8 T-cell Responses After Nanoparticle Vaccination of Melanoma PatientsSPEISER, Daniel E; SCHWARZ, Katrin; VOELTER, Verena et al.Journal of immunotherapy (1997). 2010, Vol 33, Num 8, pp 848-858, issn 1524-9557, 11 p.Article

Phase 1 Trial of Intranodal Injection of a Melan-A/MART-1 DNA Plasmid Vaccine in Patients With Stage IV MelanomaWEBER, Jeffrey; BOSWELL, William; BOT, Adrian et al.Journal of immunotherapy (1997). 2008, Vol 31, Num 2, pp 215-223, issn 1524-9557, 9 p.Article

Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1_27-35 peptide : Implications for peptide vaccinesBRINCKERHOFF, L. H; KALASHNIKOV, V. V; THOMPSON, L. W et al.International journal of cancer. 1999, Vol 83, Num 3, pp 326-334, issn 0020-7136Article

Melanoma antigen expression in serial fine-needle aspiration samples in patients with metastatic malignant melanoma participating in immunotherapy clinical trials a preliminary lookFETSCH, Patricia A; STEINBERG, Seth M; RIKER, Adam I et al.Cancer. 2001, Vol 93, Num 6, pp 409-414, issn 0008-543XArticle

Melanoma peptide MART-1(27-35) analogues with enhanced binding capacity to the human class I histocompatibility molecule HLA-A2 by introduction of a β-amino acid residue : Implications for recognition by tumor-infiltrating lymphocytesGUICHARD, Gilles; ZERBIB, Annette; LE GAL, Frédérique-Anne et al.Journal of medicinal chemistry (Print). 2000, Vol 43, Num 20, pp 3803-3808, issn 0022-2623Article

Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigensROSENBERG, S. A; YIFAN ZHAI; ROBERTS, B et al.Journal of the National Cancer Institute. 1998, Vol 90, Num 24, pp 1894-1900, issn 0027-8874Article

Lovastatin Inhibits T-cell Proliferation While Preserving the Cytolytic Function of EBV, CMV, and MART-1-specific CTLsDAN LI; YUFENG LI; HWU, Patrick et al.Journal of immunotherapy (1997). 2010, Vol 33, Num 9, pp 975-982, issn 1524-9557, 8 p.Article

Vaccination of Melanoma Patients With Melan-A/Mart-1 Peptide and Klebsiella Outer Membrane Protein P40 as an AdjuvantLIENARD, Danielle; AVRIL, Marie-Françoise; DIETRICH, Pierre-Yves et al.Journal of immunotherapy (1997). 2009, Vol 32, Num 8, pp 875-883, issn 1524-9557, 9 p.Article

Molecular tumor markers in the blood: Early prediction of disease outcome in melanoma Patients treated with a melanoma vaccineWASCHER, Robert A; MORTON, Donald L; KUO, Christine et al.Journal of clinical oncology. 2003, Vol 21, Num 13, pp 2558-2563, issn 0732-183X, 6 p.Article

Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reactionPALMIERI, Giuseppe; ASCIERTO, Paolo A; COSSU, Antonio et al.Journal of clinical oncology. 2003, Vol 21, Num 5, pp 767-773, issn 0732-183X, 7 p.Article